Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C. Muro K, et al. Among authors: orlando m. J Gastroenterol Hepatol. 2018 Apr;33(4):814-824. doi: 10.1111/jgh.14007. Epub 2018 Feb 1. J Gastroenterol Hepatol. 2018. PMID: 28960444
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Yang CH, Simms L, Park K, Lee JS, Scagliotti G, Orlando M. Yang CH, et al. Among authors: orlando m. J Thorac Oncol. 2010 May;5(5):688-95. doi: 10.1097/JTO.0b013e3181d1273d. J Thorac Oncol. 2010. PMID: 20150825 Free article. Clinical Trial.
Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial.
Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M. Belani CP, et al. Among authors: orlando m. J Thorac Oncol. 2012 Mar;7(3):567-73. doi: 10.1097/JTO.0b013e31823d4f9d. J Thorac Oncol. 2012. PMID: 22157370 Free article. Clinical Trial.
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial.
Urba S, Hong RL, Hossain AM, Cheng R, Orlando M. Urba S, et al. Among authors: orlando m. Asia Pac J Clin Oncol. 2013 Dec;9(4):331-41. doi: 10.1111/ajco.12060. Epub 2013 Feb 26. Asia Pac J Clin Oncol. 2013. PMID: 23442047 Free article. Clinical Trial.
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial.
Lee DH, Lee JS, Wang J, Hsia TC, Wang X, Kim J, Orlando M. Lee DH, et al. Among authors: orlando m. Cancer Res Treat. 2015 Oct;47(4):616-29. doi: 10.4143/crt.2014.051. Epub 2014 Nov 24. Cancer Res Treat. 2015. PMID: 25672577 Free PMC article. Clinical Trial.
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial.
Kang JH, Ahn MJ, Kim DW, Cho EK, Kim JH, Shin SW, Wang X, Kim JS, Orlando M, Park K. Kang JH, et al. Among authors: orlando m. Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14. Cancer Res Treat. 2016. PMID: 26511807 Free PMC article. Clinical Trial.
424 results